Resumen de: US2023167149A1

CD33 ligands which are useful for the synthesis of CD33 ligand-bearing carriers, wherein said CD33 ligand bearing carriers are directly or indirectly linked to or associated with at least one anti-cancer agent, are described herein. Uses of said CD33 ligand-bearing carriers for treating and/or preventing a disease, disorder, or condition such as acute myeloid leukemia (AML) are also described. The ligands have formula (I) below.

Resumen de: US2023167505A1

Provided herein includes a method comprising analyzing circulating tumor DNA (ctDNA), for example ctDNA in plasma, from a patient with leukemia, to predict and/or determine clinical response. The leukemia can be, for example, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or chronic melomonocytic leukemia (CMML).

Resumen de: WO2023094639A1

The invention concerns the use of a transcriptomic signature based on HERVs expression to characterize new AML subtypes, and a method to determine to which AML subtype a patient pertains. The method comprises providing relationship between said 9 AML subtypes and HERVs characterized by their specific herv_id and their relationship with one of these AML subtypes, determining from a patient cell sample HERVs expression profile, determining which of the 9 AML subtypes is the most represented based on HERV expression in said cell sample, and attributing to the patient the most represented AML subtype among the 9 AML subtypes. The invention allows identifying patients with medium good or bad prognosis and treating the same with a cancer therapy against AML.

Resumen de: WO2023094640A1

The present invention concerns the use of a transcriptomic signature based on Human endogenous retroviruses (HERVs) expression to characterize leukemic stem cells. In particular, the invention allows determining the presence of Leukemic Stem Cells (LSCs) in a patient. In an aspect, the invention allows determining the presence of, or quantifying, LSCs in a patient. The invention relates to gene-related methods for the identification of high-risk acute myeloid leukemia (AML) patients, methods of predicting response to treatment, methods to evaluate (minimal) residual disease during follow-up, methods to determine relapse risk, and methods of treatment of patients following implementation of the former methods.

Resumen de: AU2021346129A1

Methods of treating a hematological malignancy using a GPRC5DxCD3 bispecific antibody are described. The hematological malignancy can be a relapsed or refractory multiple myeloma, and the GPRC5DxCD3 bispecific antibody can be talquetamab.

Resumen de: WO2023097254A1

Antibody molecules that specifically bind to CD138 in a tumor microenvironment (e.g., at acidic pH) are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.

Resumen de: AU2021374590A1

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of an anti-CD20/anti-CD3 bispecific antibody.

Resumen de: US2023167081A1

Provided herein are compounds that promote targeted degradation of IKZF2, a protein whose activity is implicated in the pathology of certain cancers (e.g., acute myeloid leukemia). Also provided are pharmaceutical compositions comprising the compounds. Also provided are methods of treating cancer, and methods of promoting the degradation of IKZF2 in a subject or biological sample by administering a compound or composition described herein.

Resumen de: US2023167196A1

The invention discloses an anti-phenacetin monoclonal antibody hybridoma cell strain AD, a preparation method and application thereof, and relates to the technical field of food safety immunodetection. The monoclonal antibody hybridoma cell strain is named monoclonal cell strain AD and the number CGMCC19681. The Phe-BA obtained by the hydrolysis of the reaction product of the phenacetin metabolite acetaminophen and ethyl 4-bromobutyrate is used as the hapten, and the hapten is coupled with the carrier protein to prepare the immunogen Phe-BA-BSA. After the mice were immunized with the immunogen Phe-BA-BSA, they were fused with myeloma cells by PEG method, screened by indirect competitive enzyme-linked immunosorbent assay and subcloned five times to obtain hybridoma cell lines. The monoclonal antibody secreted by the cell line can be made into a phenacetin detection kit, which has good affinity and detection sensitivity for phenacetin, and can be used for immunodetection of phenacetin residues in food.

Resumen de: US2023167451A1

The present disclosure provides for methods and compositions for treating cancer. A subject having lymphoma is administered an EZH2 inhibitor and an HDAC inhibitor. The combination of the EZH2 inhibitor and the HDAC inhibitor produces a synergistic effect on the cancer compared to the effect of the EZH2 inhibitor or the HDAC inhibitor alone.

Resumen de: US2023165872A1

Provided herein are methods, compositions and uses for treating subjects with diseases and conditions, such as those involving or associated with B cell maturation antigen (BCMA), involving administration of a T cell therapy, such as a BCMA-targeted T cell therapy, e.g. anti-BCMA CART cells, in combination with (S)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2, 6-dione, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, tautomer or racemic mixtures thereof, and compositions thereof, or in combination with (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, tautomer or racemic mixtures thereof, and compositions thereof. The T cell therapy includes cells that express recombinant receptors such as chimeric antigen receptors (CARs) directed against BCMA. In some embodiments, the disease or condition is a multiple myeloma, such as relapsed or refractory multiple myeloma.

Resumen de: US2023167150A1

CD33 ligands which are useful for the synthesis of CD33 ligand-bearing carriers, wherein said CD33 ligand-bearing carriers are directly or indirectly linked to or associated with at least one anti-cancer agent, are described herein. Uses of said CD33 ligand-bearing carriers for treating and/or preventing a disease, disorder, or condition such as acute myeloid leukemia (AML) are also described. The CD33 ligands have the structure of formula (I):

Resumen de: WO2023093763A1

Provided are systems and methods for immunotherapies. Immune cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered immune cell). Immune cells can be engineered to exhibit enhanced proliferation as compared to a control cell. Immune cells can be engineered to effectively and specifically target diseased cells (e.g., cancer cells) that a control cell otherwise is insufficient or unable to target. The engineered Immune cells disclosed herein can be engineered ex vivo, in vitro, and in some cases, in vivo. The engineered Immune cells that are prepared ex vivo or in vitro can be administered to a subject in need thereof to treat a disease (e.g., myeloma or solid tumors). The engineered Immune cells can be autologous to the subject. Alternatively, the engineered immune cells can be allogeneic to the subject.

Resumen de: WO2023092452A1

The present invention provides a T cell receptor (TCR) for specifically identifying an EBV LMP2 antigen, a conjugate and a fusion protein comprising the TCR, an immune cell expressing the TCR, a T cell drug containing the TCR, and the use of the TCR in preventing or treating EBV-related diseases (such as EBV-positive tumors or EBV-related lymphoproliferative disorders).

Resumen de: AU2021374594A1

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.

Resumen de: US2023165898A1

Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and/or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.

Resumen de: US2023165882A1

Methods for treating cancer (such as, e.g., acute myelogenous leukemia), enhancing maintenance of normal hematopoiesis in bone marrow, and/or mobilizing leukemia blasts in a subject in need thereof comprising administering to the subject at least one FLT3 inhibitor and at least one inhibitor chosen from E-selectin inhibitors, CXCR4 inhibitors, and heterobifunctional inhibitors of E-selectin and CXCR4.

Resumen de: AU2021374592A1

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by intravenous administration of an anti-CD20/anti-CD3 bispecific antibody (e.g., mosunetuzumab).

Resumen de: WO2022018294A1

The present invention relates to the treatment of multiple myeloma using a combination of two antibody molecules that bind to human DR5 antigen and an immunomodulatory imide drug. The present invention further relates to treatment of relapsed and/or refectory multiple myeloma.

Resumen de: EP4186901A1

The present invention provides compounds having kinase inhibitory activity. Specifically, the present invention provides compounds having a structure represented by the following formula (II). The compound of the present invention has good inhibitory activity for a variety of kinases (e.g. ALK, AXL, EGFR, and FLT3), and therefore can be used for preparing a pharmaceutical composition for treating kinase activity-related diseases (e.g. acute myeloid leukemia, etc.).

Resumen de: KR20230074421A

본 발명은 결절 외 NK/T-세포 림프종의 예후를 예측하기 위한 마커, 이를 포함하는 결절 외 NK/T-세포 림프종의 예후 예측용 키트 및 결절 외 NK/T-세포 림프종의 예후 예측방법에 관한 것으로, 결절 외 NK/T-세포 림프종의 예후 예측할 수 있는 마커들을 제공함으로써, 결절 외 NK/T-세포 림프종의 치료에 유용한 자료를 제공할 수 있다.

Resumen de: WO2023089268A1

The present invention relates to a prognostic risk score for a chemosensitive cancer, in particular acute myeloid leukemia (AML), based on somatic genetic abnormalities that affect certain genes in the mitochondrial genome.

Resumen de: WO2023089150A1

The present invention relates to the use of a specific binding molecules which binds human ANXA1 in combination with a second active agent for use in the treatment of cancer. Second active agents include thymidylate synthetase inhibitors, nucleobase analogues, checkpoint inhibitors, proteasome inhibitors, taxanes, platinum-based chemotherapy agents and nucleoside analogues. Preferred cancers for treatment are pancreatic cancer, colorectal cancer, breast cancer, lung cancer, myeloma and mantle cell lymphoma. Related kits, products and uses are also provided.

Resumen de: WO2023087105A1

Provided are methods for prognosing a clinical outcome in a subject or diagnosing the subject with high-risk or stable smoldering multiple myeloma (SMM), comprising determining a 3D telomeres organization signature of a test sample from the subject, the test sample comprising plasma cells, applying a classification model to the 3D telomeres organization signature to obtain an output classification that is indicative of the clinical outcome or diagnosis of the subject. Also provided are methods for treating a subject with high-risk or stable SMM.

Resumen de: US2023159436A1

This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, splenic, kidney, lymphatic, pancreatic, stomach, eye and thyroid cancers. The active compounds are amine, sulfonamides, amide, and urea analogs of triterpene.